50 related articles for article (PubMed ID: 38640321)
1. A commentary on "Single-cell and bulk RNA-sequence identified fibroblasts signature and CD8+ T cell - Fibroblast subtype predicting prognosis and immune therapeutic response of bladder cancer, based on machine-learning" (Int J Surg. 2024 May 17.).
Wang Z; Zhang G; Liu X; Tan G
Int J Surg; 2024 Jun; ():. PubMed ID: 38840324
[No Abstract] [Full Text] [Related]
2. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract][Full Text] [Related]
3. Machine Learning Developed a Programmed Cell Death Signature for Predicting Prognosis, Ecosystem, and Drug Sensitivity in Ovarian Cancer.
Wang L; Chen X; Song L; Zou H
Anal Cell Pathol (Amst); 2023; 2023():7365503. PubMed ID: 37868825
[TBL] [Abstract][Full Text] [Related]
4. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract][Full Text] [Related]
5. Machine learning developed a PI3K/Akt pathway-related signature for predicting prognosis and drug sensitivity in ovarian cancer.
Han X; Yang L; Tian H; Ji Y
Aging (Albany NY); 2023 Oct; 15(20):11162-11183. PubMed ID: 37851341
[TBL] [Abstract][Full Text] [Related]
6. A macrophage related signature for predicting prognosis and drug sensitivity in ovarian cancer based on integrative machine learning.
Zhao B; Pei L
BMC Med Genomics; 2023 Oct; 16(1):230. PubMed ID: 37784081
[TBL] [Abstract][Full Text] [Related]
7. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract][Full Text] [Related]
8. Machine Learning-Based Integration Develops a Macrophage-Related Index for Predicting Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
Li Z; Guo M; Lin W; Huang P
Arch Med Res; 2023 Nov; 54(7):102897. PubMed ID: 37865004
[TBL] [Abstract][Full Text] [Related]
9. Multi-omics analysis defines a cuproptosis-related prognostic model for ovarian cancer: Implication of WASF2 in cuproptosis resistance.
Wang K; Zhang Y; Ao M; Luo H; Mao W; Li B
Life Sci; 2023 Nov; 332():122081. PubMed ID: 37717621
[TBL] [Abstract][Full Text] [Related]
10. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
11. Cancer-Associated Fibroblasts in Inflammation and Antitumor Immunity.
Kennel KB; Bozlar M; De Valk AF; Greten FR
Clin Cancer Res; 2023 Mar; 29(6):1009-1016. PubMed ID: 36399325
[TBL] [Abstract][Full Text] [Related]
12. MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis.
Wang CK; Chen TJ; Tan GYT; Chang FP; Sridharan S; Yu CA; Chang YH; Chen YJ; Cheng LT; Hwang-Verslues WW
Cancer Res; 2023 Jan; 83(2):251-263. PubMed ID: 36354374
[TBL] [Abstract][Full Text] [Related]
13. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
